Subscribe   RSS Contact Us

Pines Floats Six Ideas about FDA for Trump Administration Consideration

Dec. 6, 2016 – When the dust settles post-inauguration, the Trump administration likely will be considering how it might want ... read more

Sunshine Clarifications Stripped from 21st Century Cures Act

Special Report and Commentary from Jack Angel, Coalition for Healthcare Communication Education Foundation Executive Director Nov. 30, 2016 – As ... read more

Kamp: Coalition Will Continue to Fight for Free Flow of Information

Nov. 28, 2016 – Although President-elect Donald Trump was not who the Coalition for Healthcare Communication was preparing for in ... read more

Coalition Meeting: Moving Forward in Washington, D.C.

Nov 18, 2016 – Although many in the medical marketing industry were bracing for a post-election drug pricing battle with ... read more

Kamp: Moving forward after the election

Nov. 11, 2016 – Post-election report from Coalition for Healthcare Communication Executive Director John Kamp: The pollsters and pundits sure ... read more

Speakers at FDA Off-label Hearing Call for Action that Protects Free Speech

Nov. 10, 2016 – As FDA Commissioner Robert Califf described the issues surrounding the communication of off-label uses as “numerous ... read more

Report from the Coalition Executive Director

Nov. 8, 2016 – When the votes are counted, expect many discussions on what will happen next. One thing is ... read more

Kamp to Urge FDA to Provide Clear Guidance on Off-label Communication at November Hearing

Oct. 31, 2016 – In testimony at the upcoming off-label hearing at the FDA, Coalition for Healthcare Communication Executive Director ... read more

Jenkins to Speak at CHC’s D.C. Meeting

Oct. 27, 2016 — Pam Jenkins, president of Powell Tate/Weber Shandwick, will be the keynote speaker at the Nov. 16 ... read more

Coalition Commentary: How Information Flows … or Doesn’t

Commentary from Jack Angel, Coalition for Healthcare Communication Education Foundation Executive Director Oct. 25, 2016 – The Coalition for Healthcare ... read more

Kamp: Pharma Needs to Step up to Stem Opioid Abuse

Oct. 17, 2016 – In a recent guest commentary in PM360, Coalition for Healthcare Communication Executive Director John Kamp praised ... read more

CMS Clarifies Sunshine Act CME Exclusion

Oct. 6, 2016 – The Centers for Medicare & Medicaid Services (CMS) recently clarified in a revised FAQ that manufacturers ... read more

OPDP’s Abrams: Enforcement Still a Priority, Despite Decrease in Letters

Oct. 3, 2016 – Although the FDA’s Office of Prescription Drug Promotion (OPDP) has issued just four enforcement letters in ... read more

OPDP’s Second Enforcement Letter in Two Weeks Targets Investigational Drug

Sept. 15, 2016 – Although the FDA’s Office of Prescription Drug Promotion (OPDP) has only issued four enforcement letters this ... read more

OPDP Sends Enforcement Letter for Promotion of Investigational Drug

Sept. 8, 2016 — The FDA’s Office of Prescription Drug Promotion (OPDP) takes issue with a conference panel for an ... read more

FDA to Hold Post-election Hearing on Off-label Communication

Sept. 1, 2016 – In the wake of the agency’s recent settlement with Amarin and other rulings that support the ... read more

FDA May Still Issue Four Advertising Guidances in 2016

Aug. 11, 2016 — The FDA announced Aug. 10 that it plans to issue four, much-awaited advertising-related guidance documents before ... read more

Study Shows ACA Increases Use of Rx Drugs, Decreases Out-of-pocket Spending

Aug. 19, 2016 – The Affordable Care Act (ACA) has resulted in increases in the use of prescription drugs and ... read more

Gender and Healthcare Communications

By Nick Colucci, Publicis Health CEO July 21, 2016 — I was moved by a recent op-ed in The New ... read more

Medical Associations Support Bill Exempting Journals and Textbooks from Sunshine Reporting

July 15, 2016 – More than 100 medical associations, including the American Medical Association, signed a letter of support for ... read more

Pfizer Gets in Front of Opioid Marketing Issue

July 8, 2016 – As organized medicine, politicians and the public seek to reverse the scourge of opioid addiction, Pfizer ... read more

CEOs to Coalition’s Rising Leaders: Engage in Political Process, Keep Learning

June 17, 2016 – In order to stay ahead of change, further their careers and forward the positive message of ... read more

Davidson Sums Up Past and Current State of DTC Ad Restrictions, Ad Tax Deduction

June 7, 2016 – The Advertising Coalition (TAC) Executive Director Jim Davidson gave industry’s next generation a comprehensive overview of ... read more

Congressman Jenkins to Coalition’s Rising Leaders: You Have the Power to Influence Lawmakers

May 24, 2016 – At a recent Coalition for Healthcare Communication Rising Leaders Conference, keynote speaker Rep. Evan Jenkins (R-W. ... read more

NYTimes: Ban on Drug Ads Would Also Eliminate Ad Benefits

March 14, 2016 — The American Medical Association (AMA) as well as Rep. Rosa DeLauro (D-Conn.) and Sen. Al Franken ... read more

CHC and CCC Launching Regulatory Compliance University for Agencies, Publishers

Aug. 19, 2015 – The Coalition for Healthcare Communication (CHC) is partnering with the Center for Communication Compliance (CCC) to ... read more

Author of “Pharmaphobia” Says Conflict-of-interest Regulations Are Slowing Medical Progress

June 8, 2015 – In his new book, “Pharmaphobia: How the Conflict of Interest Myth Undermines American Medical Innovation,” Tom ... read more

Previous Next

PhRMA Survey Shows That Physicians Value Industry Communication

March 31, 2011 — At a time when interaction between biopharmaceutical companies and physicians is under increased scrutiny, a recent physician survey indicates that a majority of physicians find information provided by pharmaceutical and biotech research companies and their representatives to be a valuable resource, with 94 percent of physicians reporting that information from company reps is up-to-date, useful and reliable.

Indeed, nearly eight out of 10 physicians view this information as helpful, and more than 90 percent of physicians surveyed responded that interactions with biopharmaceutical representatives allow them to learn about new indications for approved medicines, potential side effects of medicines and both emerging benefits and risks of medicines, according to the results of the survey, sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA) and released March 29.

KRC Research conducted the survey of more than 500 American Medical Association members and found that physicians consider a wide range of factors when making prescribing decisions, including their clinical knowledge, experience and each patient’s unique situation, as well as information from company representatives, company-sponsored continuing medical education (CME) courses and peer-reviewed journals.

“We hope the survey results will help people understand that the simple act of companies working with physicians does not convey that physicians’ decisions will be compromised,” Kate Connors, PhRMA director of communications, told the Coalition for Healthcare Communication. “There are many resources that physicians use to make decisions, and companies clearly can contribute to that dialogue,” she said.

The Coalition supports that position. “It is vital that healthcare professionals receive truthful, accurate information about biopharmaceuticals and medical devices,” said Coalition Executive Director John Kamp. “Interference with that communication will compromise the free flow of information between industry and physicians, which will negatively affect patient care,” he said.

According to PhRMA, 84 percent of physicians indicated that conversations with company reps also give them an opportunity to provide feedback to a company about their experiences with a specific medicine. Further, more than eight in 10 physicians surveyed said they feel positive about the contribution that pharmaceutical and biotech research companies make to healthcare quality.

The survey also addressed physician perspectives regarding company-sponsored CME programs, finding that 76 percent of the physicians surveyed have attended CME programs and found them to be a valid resource for improved clinical knowledge (98 percent), information on potential side effects (97 percent), new uses of medicines (97 percent), treatment options (97 percent) and emerging drug risks (95 percent).

Of physicians who practice in rural areas, 86 percent are especially likely to attend these programs to stay informed about medicines and treatments. “We had a hunch that these programs were very useful for rural physicians, and now the survey shows us that they are,” Connors said.

The survey also appears to show that keeping the lines of communication open between industry and physicians is a worthy goal. “Every part of the communications process is valuable … there is no one path for physicians to stay informed,” Connors added. “Industry needs to continue to be a resource.”
cheap pfizer viagra

User Comments 1

  1. This is a tough area because you have to have an educational format for the utilization process to work. No one should expect doctors to start working with new or unfamiliar drugs on their own but there is a line between education and influence that must be managed properly.

    Bill Gustafson on Jan 12, 2012 @ 12:17AM